BeiGene and Immix ink collaboration agreement for IMX-110/tislelizumab cancer study

Aug. 27, 2021 8:47 AM ETBeiGene, Ltd. (BGNE)By: SA News Team

Cancer cells vis
koto_feja/E+ via Getty Images

  • BeiGene (NASDAQ:BGNE) and Immix Biopharma announce a clinical trial and supply agreement to evaluate the safety, tolerability and efficacy of a combination of IMX-110 and tislelizumab for the treatment of various solid tumors.
  • Under the terms of the agreement, ImmixBio will evaluate the combination of IMX-110 with tislelizumab in a Phase 1/2a trial in patients with advanced solid tumors.
  • "We have high hopes that IMX-110 in combination with tislelizumab could expand the population of cancer patients experiencing extended remissions," ImmixBio CEO Ilya Rachman said.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.